Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

References

• Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011;6:59–155
   PubMedGoogle Scholar
• Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 2006;35:293–305
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375–82
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–39
   PubMed Web of Science ®Google Scholar
• Morin SN, Lix LM, Leslie WD. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res 2014;29:1675–80
   PubMed Web of Science ®Google Scholar
• Giangregorio LM, Leslie WD. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 2010;25:1400–5
   PubMed Web of Science ®Google Scholar
• Akesson K, Marsh D, Mitchell PJ, et al. Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013;24:2135–52
   PubMed Web of Science ®Google Scholar
• Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2006;32:617–29
   PubMed Web of Science ®Google Scholar
• Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010;58:650–7
   PubMed Web of Science ®Google Scholar
• O’Malley C, Balasubramanian A, Dirschl D, Ho PR, Tosi L. Osteoporosis treatment following fragility fracture remains unaddressed despite available therapies and established recommendations. J Bone Miner Res 2012;27(Suppl 1): Abstr SU0333
   Google Scholar
• Kung AW, Fan T, Xu L, et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 2013;13:7
   PubMedGoogle Scholar
• McGowan B, Bennett K, Casey MC, Doherty J, Silke C, Whelan B. Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and2008. Ir J Med Sci 2013; 182:601–8
   Google Scholar
• Teede HJ, Jayasuriya IA, Gilfillan CP. Fracture prevention strategies in patients presenting to Australian hospitals with minimal-trauma fractures: a major treatment gap. Intern Med J 2007;37:674–9
   PubMed Web of Science ®Google Scholar
• Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res 2007;461:226–30
   PubMed Web of Science ®Google Scholar
• Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J. Osteoporotic fracture: missed opportunity for intervention. Osteoporos Int 2003;14:780–4
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65
   PubMed Web of Science ®Google Scholar
• Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727–36
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012;27:1480–6
   PubMed Web of Science ®Google Scholar
• McClung M, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012;27:211–18
   PubMed Web of Science ®Google Scholar
• Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137–48
   PubMed Web of Science ®Google Scholar
• van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517–22
   PubMed Web of Science ®Google Scholar
• de Klerk G, Hegeman JH, Bronkhorst P, van der Palen J, van der Velde D, Duis HJ. The (a)-symptomatic vertebral fracture: a frequently discovered entity with clinical relevance in fracture patients screened on osteoporosis. Geriatr Orthop Surg Rehabil 2012;3:74–8
   PubMedGoogle Scholar
• Adachi JD, Adami S, Gehlbach S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc 2010;85:806–13
   PubMed Web of Science ®Google Scholar
• Oleksik AM, Ewing S, Shen W, van Schoor NM, Lips P. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861–70
   PubMed Web of Science ®Google Scholar
• Buckens CF, de Jong PA, Mali WP, Verhaar HJ, van der Graaf Y, Verkooijen HM. Prevalent vertebral fractures on chest CT: higher risk for future hip fracture. J Bone Miner Res 2014;29: 392–8
   PubMed Web of Science ®Google Scholar
• Jager PL, Jonkman S, Koolhaas W, Stiekema A, Wolffenbuttel BH, Slart RH. Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations. Osteoporos Int 2011;22:1059–68
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Davison ML, Dowd B, Thiede Call K, Johnson P, Kane RL. Predictors of patients’ perceived need for medication to prevent fracture. Med Care 2011;49:273–80
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922–8
   PubMed Web of Science ®Google Scholar
• Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122:S3–13
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventative strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. Capture the fracture. Cited 2013 May. Available from: http://www.capturethefracture.org/
   Google Scholar
• National Osteoporosis Society. Fracture Liaison Services. Cited 2013 May. Available from: http://www.nos.org.uk/page.aspx?pid = 986
   Google Scholar
• American Academy of Orthopaedic Surgeons. Recommendations for Enhancing the Care of Patients with Fragility Fractures. 2009. Cited 2013 May. Available from: http://www6.aaos.org/news/PDFopen/PDFopen.cfm?page_url = http://www.aaos.org/about/papers/position/1159.asp
   Google Scholar
• Canada O. 2010 Clinical Guidelines Slideset. 2011. Cited 2013 May. Available from: http://www.osteoporosis.ca/health-care-professionals/clinical-tools-and-resources/2010-clinical-guidelines-slideset/
   Google Scholar
• Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 2012;27:2039–46
   PubMed Web of Science ®Google Scholar
• National Bone Health Alliance. Fracture Prevention Central. Cited 2013 May. Available from: http://www.nbha.org/fpc
   Google Scholar
• National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2013. Ccited 2013 May. Available from: http://www.nof.org/files/nof/public/content/file/950/upload/523.pdf
   Google Scholar
• Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 2013;8:136
   PubMedGoogle Scholar
• Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72–81
   PubMed Web of Science ®Google Scholar
• Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 2013;121:1291–9
   PubMed Web of Science ®Google Scholar
• Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 2014;58:48–54
   PubMed Web of Science ®Google Scholar
• Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int 2012;23:797–809
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757–64
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459–68
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816–22
   PubMed Web of Science ®Google Scholar